Mutations in the Ras-Raf axis underlie the prognostic value of CD133 in colorectal cancer

Clinical Cancer Research

Volumn 18, Issue 11, 2012, Pages 3132-3141

  Kemper, Kristel ^a   Versloot, Miranda ^a   Cameron, Katherine ^a   Colak, Selçuk ^a   De Sousa E Melo, Felipe ^a   De Jong, Joan H ^a   Bleackley, Joanne ^a   Vermeulen, Louis ^a   Versteeg, Rogier ^a   Koster, Jan ^a   Medema, Jan Paul ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; RAF PROTEIN; RAS PROTEIN; TUMOR MARKER;

ANTIGEN EXPRESSION; ARTICLE; B RAF GENE; CANCER PROGNOSIS; CANCER RELAPSE; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE MARKER; DOWN REGULATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; TUMOR GENE; UPREGULATION;

ANTIGENS, CD; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; GENES, RAS; GLYCOPROTEINS; HUMANS; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MUTATION; NEOPLASTIC STEM CELLS; PEPTIDES; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84861767268     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3066     Document Type: Article

References (52)

1. Winder T, Lenz HJ. Molecular predictive and prognostic markers in colon cancer. Cancer Treat Rev 2010;36:550-6.
2. Artells R, Moreno I, Diaz T, Martinez F, Gel B, Navarro A, et al. Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients. Eur J Cancer 2010;46:642-9.
3. Huh JW, Park YS, Lee JH, Kim HR, Shin MG, Kim YJ. CD133 mRNA expression and microsatellite instability in colorectal carcinoma. J Surg Oncol 2010;102:765-70.
4. Ong CW, Kim LG, Kong HH, Low LY, Iacopetta B, Soong R, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mo Pathol 2010;23:450-7.
5. Li CY, Li BX, Liang Y, Peng RQ, Ding Y, Xu DZ, et al. Higher percentage of CD133(+) cells is associated with poor prognosis in colon carcinoma patients with stage IIIB. J Trans Med 2009;7:56.
6. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009;16:3488-98.
7. Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Kawamoto A, et al. Immunohistochemical features ofCD133 expression: association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 2010;24:345-50.
8. Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/ CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004;57:1160-4. (Pubitemid 39486521)
9. Visca P, Del Nonno F, Botti C, Marandino F, Sebastiani V, Di Tondo U, et al. Role and prognostic significance of CD44s expression in colorectal cancer. Anticancer Res 2002;22:2671-5. (Pubitemid 36069296)
10. Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis. Scand J Gastroenterol 1998;33: 301-9. (Pubitemid 28156922)
11. Takahashi H, Ishii H, Nishida N, Takemasa I, Mizushima T, Ikeda M, et al. Significance of Lgr5(+ve) cancer stem cells in the colon and rectum. Ann Surg Oncol 2011;18:1166-74.
12. Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010;24:1201-12.
13. Horst D, Scheel SK, Liebmann S, Neumann J, Maatz S, Kirchner T, et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009;219:427-34.
14. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest 2009;27:844-50.
15. Kojima M, Ishii G, Atsumi N, Nishizawa Y, Saito N, Ochiai A. CD133 expression in rectal cancer after preoperative chemoradiotherapy. Cancer Sci 2010;101:906-12.
16. Vermeulen L, Todaro M, de Sousa MF, Sprick MR, Kemper K, Perez AM, et al. Single-cell cloning of colon cancer stem cells reveals a multilineage differentiation capacity. Proc Natl Acad Sci U S A 2008;105: 13427-32.
17. Chu P, Clanton DJ, Snipas TS, Lee J, Mitchell E, Nguyen ML, et al. Characterization of a subpopulation of colon cancer cells with stem cell-like properties. Int J Cancer 2009;124:1312-21.
18. Dalerba P, Dylla SJ, Park IK, Liu R, Wang XH, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-63. (Pubitemid 47175279)
19. Du L, Wang HY, He LY, Zhang JY, Ni BY, Wang XH, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-60.
20. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-10. (Pubitemid 46067310)
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-5. (Pubitemid 46067311)
22. Todaro M, Alea MP, Di Stefano AB, Cammareri P, Vermeulen L, Iovino F, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007;1:389-402. (Pubitemid 47506537)
23. Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
24. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, et al. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009;69:3382-9.
25. Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008;118:2111-20. (Pubitemid 351872330)
26. Karbanova J, Missol-Kolka E, Fonseca AV, Lorra C, Janich P, Hollerova H, et al. The stem cell marker CD133 (Prominin-1) is expressed in various human glandular epithelia. J Histochem Cytochem 2008;56: 977-93.
27. Kemper K, Sprick MR, de Bree M, Scopelliti A, Vermeulen L, Hoek M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010;70:719-29.
28. Mak AB, Blakely KM, Williams RA, Penttila PA, Shukalyuk AI, Osman KT, et al. CD133 protein N-glycosylation processing contributes to cell surface recognition of the primitive cell marker AC133 epitope. J Biol Chem 2011;286:41046-56.
29. Goh HS, Yao J, Smith DR. P53 point mutation and survival in colorectal- cancer patients. Cancer Res 1995;55:5217-21.
30. Hamelin R, Laurent Puig P, Olschwang S, Jego N, Asselain B, Remvikos Y, et al. Association of P53 mutations with short survival in colorectal-cancer. Gastroenterology 1994;106:42-8. (Pubitemid 24011863)
31. Barault L, Veyrie N, Jooste V, Lecorre D, Chapusot C, Ferraz JM, et al. Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population- based series of colon cancers. Int J Cancer 2008;122:2255-9. (Pubitemid 351542328)
32. Benhattar J, Losi L, Chaubert P, Givel JC, Costa J. Prognostic- significance of K-Ras mutations in colorectal-carcinoma. Gastroenterology 1993;104:1044-8.
33. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VEPP, Rutten HJT, et al. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 2010;21:2396-402.
34. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-74.
35. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007;7:295-308. (Pubitemid 46480970)
36. Ikenoue T, Hikiba Y, Kanai F, Tanaka Y, Imamura J, Imamura T, et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63: 8132-7. (Pubitemid 37549459)
37. Fransen K, Klintenas M, Osterstrom A, Dimberg J, Monstein HJ, Soderkvist P. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25: 527-33. (Pubitemid 38528645)
38. Melo FDE, Colak S, Buikhuisen J, Koster J, Cameron K, de Jong JH, et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011;9:476-85.
39. Bild AH, Yao G, Chang JT, Wang QL, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-7. (Pubitemid 43128862)
40. Geerts D, Koster J, Albert D, Koomoa DLT, Feith DJ, Pegg AE, et al. The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification. Int J Cancer 2010;126:2012-24.
41. Sun LX, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
42. Bos PD, Zhang XHF, Nadal C, Shu WP, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009;459:1005-9.
43. Anglesio MS, Arnold JM, George J, Tinker AV, Tothill R, Waddell N, et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008;6:1678-90.
44. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell-lines disrupted at activated Ki-Ras. Science 1993;260:85-8. (Pubitemid 23122749)
45. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, Kohsaka S, et al. Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 2008;18:1037-46.
46. Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, et al. Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008;68:8094-103.
47. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, Nishihara H, et al. Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 2010; 9:39.
48. McGlynn LM, Kirkegaard T, Edwards J, Tovey S, Cameron D, Twelves C, et al. Ras/Raf-1/MAPK pathway mediates response to tamoxifen but not chemotherapy in breast cancer patients. Clin Cancer Res 2009;15:1487-95.
49. Chen H, Tu H, Meng ZQ, Chen Z, Wang P, Liu LM. K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer. Eur J Surg Oncol 2010;36:657-62.
50. Chen L, Shi Y, Jiang CY, Wei LX, Wang YL, Dai GH. Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma. Eur J Surg Oncol 2011;37:513-20.
51. Wegman P, Ahlin C, Sorbe B. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. Int J Gynecol Cancer 2011;21:86-91.
52. Vermeulen L, Melo FDSE, van der Heijden M, Cameron K, de Jong JH, Borovski T, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nature Cell Biol 2010; 12:468-76.